209 related articles for article (PubMed ID: 36448689)
1. Design and reporting of phase III oncology trials with prospective biomarker validation.
Liang F; Peng L; Wu Z; Giamas G; Stebbing J
J Natl Cancer Inst; 2023 Feb; 115(2):174-180. PubMed ID: 36448689
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. The clinical trial transparency in oncology significantly increased over the recent years.
Song SY; Kim E
J Clin Epidemiol; 2020 Mar; 119():100-108. PubMed ID: 31816417
[TBL] [Abstract][Full Text] [Related]
4. Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis.
Parker JL; Kuzulugil SS; Pereverzev K; Mac S; Lopes G; Shah Z; Weerasinghe A; Rubinger D; Falconi A; Bener A; Caglayan B; Tangri R; Mitsakakis N
Cancer Med; 2021 Mar; 10(6):1955-1963. PubMed ID: 33620160
[TBL] [Abstract][Full Text] [Related]
5. Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review.
Langrand-Escure J; Rivoirard R; Oriol M; Tinquaut F; Rancoule C; Chauvin F; Magné N; Bourmaud A
PLoS One; 2017; 12(12):e0185536. PubMed ID: 29216190
[TBL] [Abstract][Full Text] [Related]
6. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the yield of phase II combination therapy trials in medical oncology.
Maitland ML; Hudoba C; Snider KL; Ratain MJ
Clin Cancer Res; 2010 Nov; 16(21):5296-302. PubMed ID: 20837695
[TBL] [Abstract][Full Text] [Related]
8. Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials.
Salawu A; Hernando-Calvo A; Chen RY; Araujo DV; Oliva M; Liu ZA; Siu LL
Eur J Cancer; 2022 Sep; 173():167-177. PubMed ID: 35872510
[TBL] [Abstract][Full Text] [Related]
9. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
Vickers AJ; Ballen V; Scher HI
Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
[TBL] [Abstract][Full Text] [Related]
10. A Problematic Biomarker Trial Design.
Freidlin B; Korn EL
J Natl Cancer Inst; 2022 Feb; 114(2):187-190. PubMed ID: 34289052
[TBL] [Abstract][Full Text] [Related]
11. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
Addeo A; Weiss GJ; Gyawali B
JAMA Netw Open; 2019 May; 2(5):e193684. PubMed ID: 31074821
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the quality of the reporting of phase II clinical trials in oncology: A systematic review.
Rivoirard R; Langrand-Escure J; Oriol M; Tinquaut F; Chauvin F; Rancoule C; Magné N; Bourmaud A
Crit Rev Oncol Hematol; 2018 May; 125():78-83. PubMed ID: 29650280
[TBL] [Abstract][Full Text] [Related]
13. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
[TBL] [Abstract][Full Text] [Related]
14. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
[TBL] [Abstract][Full Text] [Related]
15. A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development.
Chen C; Anderson K; Mehrotra DV; Rubin EH; Tse A
Contemp Clin Trials; 2018 Jan; 64():238-242. PubMed ID: 28966137
[TBL] [Abstract][Full Text] [Related]
16. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines.
Mistry P; Dunn JA; Marshall A
BMC Med Res Methodol; 2017 Jul; 17(1):108. PubMed ID: 28720094
[TBL] [Abstract][Full Text] [Related]
17. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.
Zhang S; Liang F; Li W; Hu X
J Clin Oncol; 2015 May; 33(15):1697-702. PubMed ID: 25897150
[TBL] [Abstract][Full Text] [Related]
18. Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology.
Bariani GM; de Celis Ferrari AC; Hoff PM; Krzyzanowska MK; Riechelmann RP
J Clin Oncol; 2013 Jun; 31(18):2289-95. PubMed ID: 23630201
[TBL] [Abstract][Full Text] [Related]
19. Innovation in oncology clinical trial design.
Verweij J; Hendriks HR; Zwierzina H;
Cancer Treat Rev; 2019 Mar; 74():15-20. PubMed ID: 30665053
[TBL] [Abstract][Full Text] [Related]
20. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.
Raghav KP; Mahajan S; Yao JC; Hobbs BP; Berry DA; Pentz RD; Tam A; Hong WK; Ellis LM; Abbruzzese J; Overman MJ
J Clin Oncol; 2015 Nov; 33(31):3583-90. PubMed ID: 26304898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
